Company presentations 2025

Short peptides as effective treatment for Wilson disease

metaLead Therapeutics

metaLead is a spin-out from the University of Zurich pioneering innovative therapies for metal-related diseases. Our platform develops first-in-class metal-binding peptides with exceptional affinity and selectivity to desired metals. Our lead program addresses Wilson disease, a rare genetic condition causing the accumulation of toxic amounts of copper in the liver and brain. We combine cutting-edge science, drug development expertise, and patient-driven innovation.

Name	Position	Institution
Michal Shoshan	Chief Executive Officer